Leo I. Gordon MD
Despite major progress with chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors in hematologic malignancies, questions remain regarding the use of these therapies in this landscape, according to Leo I. Gordon, MD.
on Hematologic Malignancies, Gordon, a professor of medicine at Feinberg School of Medicine, Northwestern University, and chair of the meeting, discussed promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.
OncLive: There have a handful of recent FDA approvals and encouraging clinical trial results across the field of hematologic cancers. What is most notable to mention?
: In the beginning [of the conference], Dr Olga Frankfurt spoke about acute myeloid leukemia (AML). The highlight there is better understanding of the disease and better understanding of the molecular biology. The big question for AML is, “When will that translate into better outcomes?” We've been struggling with that for years, but Dr Frankfurt had some exciting data. She also spoke about novel clinical trials that are based upon some of the molecular defects that have now been uncovered. We're beginning to make progress in AML.
... to read the full story